Synapse Fund

Synapse Biomedical is a commercial-stage medical device company specializing in the development of minimally invasive neurostimulation systems for patients with respiratory insufficiency. The company's flagship product, the NeuRx Diaphragm Pacing System (DPS), is an FDA-approved device designed to provide electrical stimulation to the phrenic nerves, causing the diaphragm to contract and allowing patients to breathe more naturally. This technology is primarily utilized for patients with spinal cord injuries and Amyotrophic Lateral Sclerosis (ALS) who are dependent on mechanical ventilation. By reducing or eliminating the need for mechanical ventilators, Synapse Biomedical aims to improve the quality of life and reduce healthcare costs for patients with chronic respiratory failure.